Virios Therapeutics, Inc. (VIRI)
| Previous close | 4.9500 |
| Open | 4.8100 |
| Bid | 4.7000 x 1100 |
| Ask | 4.9500 x 900 |
| Day's range | 4.7500 - 4.9500 |
| 52-week range | 4.0000 - 16.7100 |
| Volume | 20,338 |
| Avg. volume | 31,644 |
| Market cap | 41.235M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.3780 |
| Earnings date | 12 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.50 |
- Business Wire
Virios Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
ATLANTA, November 11, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended September 30, 2021 and provided a corporate update at 8:30 a.m. EST.
- Business Wire
Virios Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on Thursday, November 11, 2021
ATLANTA, November 04, 2021--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced today that its third quarter 2021 financial results will be reported on Thursday, November 11, 2021 before the open of the financial markets. Management will also host a webcast and conference call on November 11, 2021 at 8:30 a.m. ET to discuss the results and provide a corpora
- Simply Wall St.
Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
